A Search Service for Abbreviation / Long Form

■ 検索結果 - 略語 : KRAS

検索条件:
検索語 : KRAS
検索方法 : 完全一致
主な研究分野:

結果:  
略語: KRAS
出現頻度: 868
対応する展開形の数: 28

表示設定:
[1ページの件数]
ページ移動
/ ページ
展開形 No. 展開形 主な研究分野 共起略語 PubMed/MEDLINE情報 (発表年, 題目)
Kirsten rat sarcoma viral oncogene homolog
<Kirsten rat sarcoma virus 由来,がん遺伝子>
(545 回)
Neoplasms
新生物, 腫瘍
(258 回)
EGFR (202 回)
NSCLC (133 回)
CRC (78 回)
2006 Genotype-specific signal generation based on digestion of 3-way DNA junctions: application to KRAS variation detection.
Kirsten rat sarcoma
(113 回)
Neoplasms
新生物, 腫瘍
(51 回)
NSCLC (34 回)
EGFR (28 回)
CRC (13 回)
2009 Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9.
Kirsten ras
(91 回)
Neoplasms
新生物, 腫瘍
(40 回)
CRC (19 回)
EGFR (17 回)
mCRC (7 回)
1990 Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation.
KRAS proto-oncogene, GTPase
(34 回)
Neoplasms
新生物, 腫瘍
(15 回)
BRAF (7 回)
TP53 (7 回)
CRC (5 回)
2016 Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors.
Kirsten rat sarcoma virus
(30 回)
Neoplasms
新生物, 腫瘍
(13 回)
EGFR (6 回)
PDAC (6 回)
NSCLC (5 回)
2012 High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
KRAS proto-oncogene
(12 回)
Neoplasms
新生物, 腫瘍
(7 回)
BRAF (4 回)
EGFR (3 回)
PIK3CA (3 回)
2016 Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Kirsten ras oncogene
(11 回)
Neoplasms
新生物, 腫瘍
(6 回)
EGFR (5 回)
CRC (3 回)
ALK (1 回)
1996 Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter: KRAS expression in thyroids analyzed by in situ hybridization.
KRASwt
(6 回)
Neoplasms
新生物, 腫瘍
(3 回)
EGFR (2 回)
CCR7 (1 回)
DFS (1 回)
2011 Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.
K-ras oncogene
K-ras癌遺伝子
(3 回)
Neoplasms
新生物, 腫瘍
(2 回)
EGFR (2 回)
HADS (1 回)
mCRC (1 回)
2010 Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.
10  Kirsten ras oncogene homolog
(3 回)
Neoplasms
新生物, 腫瘍
(3 回)
EGFR (2 回)
DIA (1 回)
EGFR-TKI (1 回)
2008 Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
11  Kristen Rat Sarcoma
(3 回)
Neoplasms
新生物, 腫瘍
(2 回)
ALK (1 回)
CP (1 回)
CRCs (1 回)
2014 Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India.
12  Ki-Ras
(1 回)
Cell Biology
細胞生物学
(1 回)
--- 2006 Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes.
13  kirsten human rat sarcoma protein
(1 回)
Neoplasms
新生物, 腫瘍
(1 回)
ALK (1 回)
EGFR (1 回)
mTOR (1 回)
2019 Targeted therapies for advanced non-small cell lung cancer.
14  kirsten RAS viral oncogene homolog
(1 回)
Hematology
血液学
(1 回)
AML (1 回)
CDK1 (1 回)
mTOR (1 回)
2014 Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.
15  Kirsten rat sarcoma virus transforming protein
(1 回)
NSCLC (1 回)
2021 Untangling the KRAS mutated lung cancer subsets and its therapeutic implications.
16  Kirsten Rat Sarcoma-activating mutations
(1 回)
EMT (1 回)
FGF-2 (1 回)
FGFR2c (1 回)
2022 The FGFR2c/PKCε Axis Controls MCL-1-Mediated Invasion in Pancreatic Ductal Adenocarcinoma Cells: Perspectives for Innovative Target Therapies.
17  Kirsten retrovirus-associated DNA sequences
(1 回)
Neoplasms
新生物, 腫瘍
(1 回)
APC (1 回)
ARID1A (1 回)
ATM (1 回)
2019 Genetic Aberration Analysis in Thai Colorectal Adenoma and Early-Stage Adenocarcinoma Patients by Whole-Exome Sequencing.
18  Kirsten RSAS
(1 回)
Neoplasms
新生物, 腫瘍
(1 回)
5-FU (1 回)
DCR (1 回)
LC (1 回)
2018 The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer.
19  Kirsten-rous avian sarcoma
(1 回)
Neoplasms
新生物, 腫瘍
(1 回)
EGFR (1 回)
IGF-1 (1 回)
MET (1 回)
2011 Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
20  KRAS and NRAS were analyzed
(1 回)
Natural Science Disciplines

(1 回)
EGFR (1 回)
mCRC (1 回)
2019 KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer patients in 2015.
21  KRAS gene
(1 回)
Neoplasms
新生物, 腫瘍
(1 回)
ACM (1 回)
CRC (1 回)
CSM (1 回)
2019 Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta-analysis.
22  KRAS inhibitors BI-3406
(1 回)
Neoplasms
新生物, 腫瘍
(1 回)
PDAC (1 回)
2022 Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines.
23  KRAS onc
(1 回)
Neoplasms
新生物, 腫瘍
(1 回)
--- 2019 From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers.
24  KRAS wildtype
(1 回)
Gastroenterology
胃腸病学
(1 回)
BRAF (1 回)
CRC (1 回)
RR (1 回)
2017 Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes.
25  KRAS-4B
(1 回)
Chemistry
化学
(1 回)
MD (1 回)
PBD (1 回)
PC (1 回)
2022 Phosphatidylserine and Phosphatidylethanolamine Asymmetry Have a Negligible Effect on the Global Structure, Dynamics, and Interactions of the KRAS Lipid Anchor.
26  KRAS-siRNA
(1 回)
Pharmacology
薬理学, 薬理, 薬品作用学
(1 回)
GEM (1 回)
2020 Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
27  KRASmut
(1 回)
Neoplasms
新生物, 腫瘍
(1 回)
PDAC (1 回)
TGF-beta (1 回)
2021 Role of PLEXIND1/TGFβ Signaling Axis in Pancreatic Ductal Adenocarcinoma Progression Correlates with the Mutational Status of KRAS.
28  Kristen-ras
(1 回)
Neoplasms
新生物, 腫瘍
(1 回)
APC (1 回)
CRC (1 回)
HCECs (1 回)
2021 Short-Term and Long-Term Carcinogenic Effects of Food Contaminants (4-Hydroxynonenal and Pesticides) on Colorectal Human Cells: Involvement of Genotoxic and Non-Genomic Mechanisms.